Biogen Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year) increased by 11.6% to $900.80M in Q1 2026 compared to the prior quarter. Over 3 years (FY 2020 to FY 2025), Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year) shows a downward trend with a -14.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Higher levels indicate strong short-term liquidity, while lower levels might suggest a reliance on other funding sources or a strategy to reinvest in longer-term assets.
This metric measures the amortized cost of available-for-sale debt securities that are scheduled to mature within one ye...
Standard metric for all financial institutions to demonstrate short-term solvency and cash flow management.
afs_debt_securities_amortized_cost_1y| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.31B | $1.41B | $1.54B | $2.00B | $2.15B | $1.24B | $1.48B | $2.15B | $3.47B | $97.60M | $807.20M | $900.80M |
| QoQ Change | — | +8.0% | +9.1% | +29.9% | +7.4% | -42.6% | +20.1% | +45.0% | +61.2% | -97.2% | +727.0% | +11.6% |
| YoY Change | — | — | — | — | +64.4% | -12.6% | -3.8% | +7.4% | +61.2% | — | — | — |